According to Frost & Sullivan, as of the Latest Practicable Date, our Core Product, bezacitinib, is expected to become one of the first three domestically developed JAK inhibitors in China to be approved for myelofibrosis (MF). In terms of clinical progress, bezacitinib ranks as the first JAK inhibitor in China for polycythemia vera (PV), and the first JAK inhibitor globally for essential thrombocythemia (ET). Our other Core Product, CX1440, is one of the first three BTK inhibitors globally in terms of clinical progress for immune thrombocytopenia (ITP) and one of the first two globally in terms of clinical progress for each of chronic urticaria (CU) and autoimmune hemolytic anemia (AIHA).